Abstract
The spectrum of gut microbiome composition is readily but controversially distilled into a handful of community types. In this issue of <i>Cell Host & Microbe</i>, Lee et al. (2021) find that matching pre-existing community types (and associated molecular biomarkers) to the class of immune biologic therapy in inflammatory bowel disease may double the treatment response.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have